Neville Wei Yang Teo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neville Wei Yang Teo has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Tze Choong Charn
Department of Otorhinolaryngology—Head & Neck Surgery Singapore General Hospital Singapore Singapore
5 shared publications - Benjamin Kye Jyn Tan
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
4 shared publications - Claire Jing‐Wen Tan
Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
4 shared publications - Shuhui Xu
Department of Otorhinolaryngology—Head and Neck Surgery, Singapore General Hospital, Singapore
4 shared publications - Song Tar Toh
Singapore General Hospital
4 shared publications - Anna See
Department of Otorhinolaryngology–Head & Neck Surgery Singapore General Hospital Singapore
3 shared publications
Latest Publications
- 22 July 2026
- Published by Wiley in Head & Neck
Trends of EBV Serology in Screening of Nasopharyngeal Cancer in a Multiethnic Healthy Singaporean Cohort
Background: Epstein–Barr virus–positive nasopharyngeal carcinoma (EBV‐NPC) is highly prevalent in Asia. EBV IgA serologies (targeting viral capsid antigen [VCA] and early antigen [EA]) are commonly used for NPC screening in Singapore. However, the predictive value of longitudinal serologic trends in real‐world screening remains unclear. This study evaluated EBV IgA serologic patterns and their relationship with NPC development. Methods: We conducted a retrospective cohort study of 1977 asymptomatic individuals screened for NPC between 2008 and 2021 at a tertiary medical center in Singapore. Patients were predominantly Chinese (95%) and aged 12–90 years. Data on EBV IgA serologies (EA‐IgA and VCA‐IgA), plasma EBV DNA, nasoendoscopy, biopsies, and MRI findings were collected. Primary outcomes included EBV serologic trends (stratified into positive for only one serology type, non‐fluctuating positivity, fluctuating positivity, seroconversion or seroreversion) and incidence of NPC during follow‐up. Results: Of the 1977 patients, 62% tested positive for either EA‐IgA or VCA‐IgA. 7.2% showed stable positive titers, 5% had fluctuating titers, 2.4% seroconverted, and 23.5% seroreverted. Six patients (0.3%) developed NPC; all were Chinese, with a mean age of 50. Three had Stage I, one had Stage III, and two had Stage IV disease. Their serologic trajectories varied with no consistent pattern observed. Elevated EBV EA‐IgA (2/6) or VCA‐IgA (2/6) titers were observed 1–2 years before diagnosis. Conclusion: No consistent EBV serologic pattern preceded NPC diagnosis in this cohort. The low NPC detection rate of 0.3% suggests limited screening utility of EBV serologies in a heterogeneous, intermediate‐risk population.
- 22 July 2026
- Published by Wiley in Head & Neck
Trends of EBV Serology in Screening of Nasopharyngeal Cancer in a Multiethnic Healthy Singaporean Cohort
Background: Epstein–Barr virus–positive nasopharyngeal carcinoma (EBV‐NPC) is highly prevalent in Asia. EBV IgA serologies (targeting viral capsid antigen [VCA] and early antigen [EA]) are commonly used for NPC screening in Singapore. However, the predictive value of longitudinal serologic trends in real‐world screening remains unclear. This study evaluated EBV IgA serologic patterns and their relationship with NPC development. Methods: We conducted a retrospective cohort study of 1977 asymptomatic individuals screened for NPC between 2008 and 2021 at a tertiary medical center in Singapore. Patients were predominantly Chinese (95%) and aged 12–90 years. Data on EBV IgA serologies (EA‐IgA and VCA‐IgA), plasma EBV DNA, nasoendoscopy, biopsies, and MRI findings were collected. Primary outcomes included EBV serologic trends (stratified into positive for only one serology type, non‐fluctuating positivity, fluctuating positivity, seroconversion or seroreversion) and incidence of NPC during follow‐up. Results: Of the 1977 patients, 62% tested positive for either EA‐IgA or VCA‐IgA. 7.2% showed stable positive titers, 5% had fluctuating titers, 2.4% seroconverted, and 23.5% seroreverted. Six patients (0.3%) developed NPC; all were Chinese, with a mean age of 50. Three had Stage I, one had Stage III, and two had Stage IV disease. Their serologic trajectories varied with no consistent pattern observed. Elevated EBV EA‐IgA (2/6) or VCA‐IgA (2/6) titers were observed 1–2 years before diagnosis. Conclusion: No consistent EBV serologic pattern preceded NPC diagnosis in this cohort. The low NPC detection rate of 0.3% suggests limited screening utility of EBV serologies in a heterogeneous, intermediate‐risk population.
- Open Access
- 11 August 2025
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Outcomes in Orbit‐Sparing Versus Orbit‐Sacrificing Surgery for Sinonasal Malignancies With Orbital Involvement: A Systematic Review and Meta‐Analysis
Background: Sinonasal malignancies with orbital involvement may be managed with orbit‐sacrificing or orbit‐preserving surgical approaches, with a recent shift towards orbital preservation to reduce postoperative morbidity while maintaining oncological success. The current clinical data on the most optimal approach for managing such locally advanced tumours remains inconclusive.Methods: PubMed, Embase, and SCOPUS were searched from inception to 12 June 2024 for longitudinal studies investigating oncological and functional outcomes in sinonasal malignancies with orbital involvement managed with orbit‐sacrificing vs. orbit‐preserving surgery. Two independent authors selected relevant articles, extracted data, assessed bias using the Newcastle‐Ottawa Scale and evaluated quality of evidence following the Grading of Recommendations, Assessment, Development and Evaluations framework. Random‐effects meta‐analysis was performed to synthesise pooled oncological outcomes, while descriptive reviews were performed for functional outcomes.Results: This systematic review and meta‐analysis of 12 studies and 758 participants found that the 5‐year overall survival rate of patients managed with orbit‐preserving surgery (55%, 95% CI: 0.32–0.76) was comparable to that in patients managed with orbit‐sacrificing surgery (53%, 95% CI: 0.34–0.70). The 5‐year recurrence‐free survival rate was significantly higher in patients managed with orbit‐preserving surgical intervention (64%, 95% CI: 0.44–0.80), compared to those with orbit‐sacrificing surgery (48%, 95% CI: 0.13–0.84). Descriptive review showed good functional outcomes in patients managed with orbit‐preserving surgery.Conclusion: Orbit‐preserving surgery in selected cases of sinonasal malignancies with orbital involvement is oncologically safe and can allow for the maintenance of a functionally useful eye. Greater number of large‐scale, robust studies are required to further evaluate the outcomes in tumours with different characteristics.
- 11 August 2025
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Open AccessOutcomes in Orbit‐Sparing Versus Orbit‐Sacrificing Surgery for Sinonasal Malignancies With Orbital Involvement: A Systematic Review and Meta‐Analysis
Background: Sinonasal malignancies with orbital involvement may be managed with orbit‐sacrificing or orbit‐preserving surgical approaches, with a recent shift towards orbital preservation to reduce postoperative morbidity while maintaining oncological success. The current clinical data on the most optimal approach for managing such locally advanced tumours remains inconclusive.Methods: PubMed, Embase, and SCOPUS were searched from inception to 12 June 2024 for longitudinal studies investigating oncological and functional outcomes in sinonasal malignancies with orbital involvement managed with orbit‐sacrificing vs. orbit‐preserving surgery. Two independent authors selected relevant articles, extracted data, assessed bias using the Newcastle‐Ottawa Scale and evaluated quality of evidence following the Grading of Recommendations, Assessment, Development and Evaluations framework. Random‐effects meta‐analysis was performed to synthesise pooled oncological outcomes, while descriptive reviews were performed for functional outcomes.Results: This systematic review and meta‐analysis of 12 studies and 758 participants found that the 5‐year overall survival rate of patients managed with orbit‐preserving surgery (55%, 95% CI: 0.32–0.76) was comparable to that in patients managed with orbit‐sacrificing surgery (53%, 95% CI: 0.34–0.70). The 5‐year recurrence‐free survival rate was significantly higher in patients managed with orbit‐preserving surgical intervention (64%, 95% CI: 0.44–0.80), compared to those with orbit‐sacrificing surgery (48%, 95% CI: 0.13–0.84). Descriptive review showed good functional outcomes in patients managed with orbit‐preserving surgery.Conclusion: Orbit‐preserving surgery in selected cases of sinonasal malignancies with orbital involvement is oncologically safe and can allow for the maintenance of a functionally useful eye. Greater number of large‐scale, robust studies are required to further evaluate the outcomes in tumours with different characteristics.
- Open Access
- 10 July 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1347-1358
Olfactory Impairment and Incident Cognitive Decline: A Systematic Review and Meta‐Analysis
Background: Olfactory impairment (OI) is associated with poor ageing outcomes. While cross‐sectional studies found a high prevalence of OI among patients with neurodegenerative diseases, the temporal relationship remains unclear. This meta‐analysis aims to synthesise the longitudinal association of OI with cognitive decline (CD). Methods: PubMed, Embase and Web of Science were searched through August 9, 2024 for longitudinal studies reporting on self‐reported and objectively measured OI in adults, in association with CD, measured using validated methods. The outcome of interest was incident CD. Independent authors extracted data, assessed for bias and graded the strength of evidence. A mixed‐effects meta‐analysis with subgroup, sensitivity and bias analyses was conducted. The population‐attributable fraction (PAF) of OI‐associated CD was calculated. Results: This study included 48 articles and 37,783 participants. OI patients had a 2.06‐fold greater risk of any CD (risk ratio [RR] = 2.06; 95% CI = 1.87‒2.26, I 2 = 0%), compared to individuals with normal olfaction. Patients with severe OI had a higher risk of any CD (RR = 2.60; 95% CI = 2.12‒3.20, I 2 = 0%) than patients with moderate OI (RR = 1.51; 95% CI = 1.23‒1.85, I 2 = 0%). The risk of any CD increased by 18% per 10% decrease in olfactory score (RR = 1.18; 95% CI = 1.14‒1.22, I 2 = 24%) and by 15% per point decrement on the Sniffin’ Sticks Odor Identification Test (RR = 1.15; 95% CI = 1.11‒1.18, I 2 = 0%). These results remained robust to supplementary analyses. The PAF of OI‐associated incident CD was 18%. Conclusion: OI may increase the risk of CD, with poorer olfaction linked to greater risks. OI should be assessed as a potential cognitive screening tool, and cognitive screening should be considered in patients with long‐standing OI.
- 10 July 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1347-1358
Open AccessOlfactory Impairment and Incident Cognitive Decline: A Systematic Review and Meta‐Analysis
Background: Olfactory impairment (OI) is associated with poor ageing outcomes. While cross‐sectional studies found a high prevalence of OI among patients with neurodegenerative diseases, the temporal relationship remains unclear. This meta‐analysis aims to synthesise the longitudinal association of OI with cognitive decline (CD). Methods: PubMed, Embase and Web of Science were searched through August 9, 2024 for longitudinal studies reporting on self‐reported and objectively measured OI in adults, in association with CD, measured using validated methods. The outcome of interest was incident CD. Independent authors extracted data, assessed for bias and graded the strength of evidence. A mixed‐effects meta‐analysis with subgroup, sensitivity and bias analyses was conducted. The population‐attributable fraction (PAF) of OI‐associated CD was calculated. Results: This study included 48 articles and 37,783 participants. OI patients had a 2.06‐fold greater risk of any CD (risk ratio [RR] = 2.06; 95% CI = 1.87‒2.26, I 2 = 0%), compared to individuals with normal olfaction. Patients with severe OI had a higher risk of any CD (RR = 2.60; 95% CI = 2.12‒3.20, I 2 = 0%) than patients with moderate OI (RR = 1.51; 95% CI = 1.23‒1.85, I 2 = 0%). The risk of any CD increased by 18% per 10% decrease in olfactory score (RR = 1.18; 95% CI = 1.14‒1.22, I 2 = 24%) and by 15% per point decrement on the Sniffin’ Sticks Odor Identification Test (RR = 1.15; 95% CI = 1.11‒1.18, I 2 = 0%). These results remained robust to supplementary analyses. The PAF of OI‐associated incident CD was 18%. Conclusion: OI may increase the risk of CD, with poorer olfaction linked to greater risks. OI should be assessed as a potential cognitive screening tool, and cognitive screening should be considered in patients with long‐standing OI.
- 20 October 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (1) , 29-40
Meta‐analysis of multi‐modality therapies in sinonasal undifferentiated carcinoma—A timely update
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare but aggressive tumour with very poor prognosis. There are currently no well-established clinical trials to guide therapy and the impact of various treatment modalities on survival is not well defined. We aim to provide an updated systematic review on current treatment modalities on survival outcomes.Design and Setting: Individual patient data were extracted, and survival data pooled in a one-stage meta-analysis. Descriptive statistics were analysed using the Kaplan-Meier method. Patient-level comparisons stratified by treatment modalities, adjusted for demographics, were conducted using shared-frailty Cox regression.Participants and Main outcome measures: Participants include all patients diagnosed with SNUC based on histological evidence. We looked at the overall cumulative survival outcome for different treatment modalities and overall survival by treatment modality in low versus high stage SNUC patients.Results and Conclusion: Seventeen studies were identified, comprising 208 patients from 1993 to 2020. There was no significant difference in cumulative overall survival in low versus high stage patients, and no significant difference in outcomes by treatment modality. The overall cumulative survival of SNUC is 30% at 95 months. Among patients treated with various combinations of treatment modalities, patients with chemoradiotherapy had the highest cumulative survival of 42% at 40 months. Definitive chemoradiotherapy was associated with improved disease survival rate. Regardless of tumour stage, patients should be treated early and aggressively, with no superiority of one treatment regimen over another. Trimodality treatment does not confer survival advantage over bimodality treatment.
- 20 October 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (1) , 29-40
Meta‐analysis of multi‐modality therapies in sinonasal undifferentiated carcinoma—A timely update
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare but aggressive tumour with very poor prognosis. There are currently no well-established clinical trials to guide therapy and the impact of various treatment modalities on survival is not well defined. We aim to provide an updated systematic review on current treatment modalities on survival outcomes.Design and Setting: Individual patient data were extracted, and survival data pooled in a one-stage meta-analysis. Descriptive statistics were analysed using the Kaplan-Meier method. Patient-level comparisons stratified by treatment modalities, adjusted for demographics, were conducted using shared-frailty Cox regression.Participants and Main outcome measures: Participants include all patients diagnosed with SNUC based on histological evidence. We looked at the overall cumulative survival outcome for different treatment modalities and overall survival by treatment modality in low versus high stage SNUC patients.Results and Conclusion: Seventeen studies were identified, comprising 208 patients from 1993 to 2020. There was no significant difference in cumulative overall survival in low versus high stage patients, and no significant difference in outcomes by treatment modality. The overall cumulative survival of SNUC is 30% at 95 months. Among patients treated with various combinations of treatment modalities, patients with chemoradiotherapy had the highest cumulative survival of 42% at 40 months. Definitive chemoradiotherapy was associated with improved disease survival rate. Regardless of tumour stage, patients should be treated early and aggressively, with no superiority of one treatment regimen over another. Trimodality treatment does not confer survival advantage over bimodality treatment.
- 14 October 2022
- Published by Stichting Nase in Rhinology Online
- Vol. 5 (5) , 142-148
Endotyping of nasal polyps in a multiracial Asian population
Background: Chronic rhinosinusitis is a heterogenous disease with variation in the endotypes of nasal polyps, with type 2 inflammation being more prevalent in Caucasian populations whereas Chinese populations are more heterogenous. We aim to describe the variation in endotypes for patients with chronic rhinosinusitis with nasal polyposis in our unique multiracial population. Methodology: Demographic, clinical and structured histopathological data of 66 patients who underwent sinus surgery for nasal polyposis were evaluated retrospectively. Results: 54.6% had eosinophilic disease, and 45.4% had non-eosinophilic disease with no significant demographic differences between the 2 populations. There were significantly higher peripheral eosinophil levels in patients with eosinophil-predominant inflammation on tissue histology (mean absolute eosinophil count 0.59 ± 0.18 x 109) compared with non-eosinophilic disease (mean absolute eosinophil count 0.24 ± 0.11 x 109). Structured histopathological reporting revealed that patients with eosinophilic disease had higher degree of inflammation and eosinophil aggregates. Conclusions: Our population is shown to have a slight preponderance toward eosinophilic disease, however the Chinese majority tended to have non-eosinophilic disease. Serum eosinophilia and the presence of asthma seems to correlate well with tissue eosinophilia, which can potentially be utilised as markers of type 2 inflammatory disease.
- 14 October 2022
- Published by Stichting Nase in Rhinology Online
- Vol. 5 (5) , 142-148
Endotyping of nasal polyps in a multiracial Asian population
Background: Chronic rhinosinusitis is a heterogenous disease with variation in the endotypes of nasal polyps, with type 2 inflammation being more prevalent in Caucasian populations whereas Chinese populations are more heterogenous. We aim to describe the variation in endotypes for patients with chronic rhinosinusitis with nasal polyposis in our unique multiracial population. Methodology: Demographic, clinical and structured histopathological data of 66 patients who underwent sinus surgery for nasal polyposis were evaluated retrospectively. Results: 54.6% had eosinophilic disease, and 45.4% had non-eosinophilic disease with no significant demographic differences between the 2 populations. There were significantly higher peripheral eosinophil levels in patients with eosinophil-predominant inflammation on tissue histology (mean absolute eosinophil count 0.59 ± 0.18 x 109) compared with non-eosinophilic disease (mean absolute eosinophil count 0.24 ± 0.11 x 109). Structured histopathological reporting revealed that patients with eosinophilic disease had higher degree of inflammation and eosinophil aggregates. Conclusions: Our population is shown to have a slight preponderance toward eosinophilic disease, however the Chinese majority tended to have non-eosinophilic disease. Serum eosinophilia and the presence of asthma seems to correlate well with tissue eosinophilia, which can potentially be utilised as markers of type 2 inflammatory disease.
- Top Cited PapersOpen Access
Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
Objective: To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021. Review methods: Two blinded reviewers selected observational studies of adults (≥18 years) with covid-19 related dysfunction of smell or taste. Descriptive prognosis studies with time-to-event curves and prognostic association studies of any prognostic factor were included. Data extraction and synthesis: Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull non-mixture cure models of plateaued survival curves were logit transformed and pooled in a two stage meta-analysis. Conventional aggregate data meta-analysis was performed to explore unadjusted associations of prognostic factors with recovery. Main outcome measures: The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste. Results: 18 studies (3699 patients) from 4180 records were included in reconstructed IPD meta-analyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent self-reported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%, I 2 =70%, τ 2 =0.756, 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%, I 2 =67%, τ 2 =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell (I 2 =0.0-77.2%, τ 2 =0.006-0.050) and 78.8% (70.5% to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of I 2 =0.0-72.1%, τ 2 =0.000-0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies, I 2 =20%, τ 2 =0.0224) and taste (0.31, 0.13 to 0.72, seven studies, I 2 =78%, τ 2 =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies, I 2 =10%, τ 2 2 =0%, τ 2 <0.001) were less likely to recover their sense of smell. Conclusions: A substantial proportion of patients with covid-19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid. Systematic review registration: PROSPERO CRD42021283922.
Top Cited PapersOpen AccessPrognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
Objective: To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021. Review methods: Two blinded reviewers selected observational studies of adults (≥18 years) with covid-19 related dysfunction of smell or taste. Descriptive prognosis studies with time-to-event curves and prognostic association studies of any prognostic factor were included. Data extraction and synthesis: Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull non-mixture cure models of plateaued survival curves were logit transformed and pooled in a two stage meta-analysis. Conventional aggregate data meta-analysis was performed to explore unadjusted associations of prognostic factors with recovery. Main outcome measures: The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste. Results: 18 studies (3699 patients) from 4180 records were included in reconstructed IPD meta-analyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent self-reported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%, I 2 =70%, τ 2 =0.756, 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%, I 2 =67%, τ 2 =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell (I 2 =0.0-77.2%, τ 2 =0.006-0.050) and 78.8% (70.5% to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of I 2 =0.0-72.1%, τ 2 =0.000-0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies, I 2 =20%, τ 2 =0.0224) and taste (0.31, 0.13 to 0.72, seven studies, I 2 =78%, τ 2 =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies, I 2 =10%, τ 2 2 =0%, τ 2 <0.001) were less likely to recover their sense of smell. Conclusions: A substantial proportion of patients with covid-19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid. Systematic review registration: PROSPERO CRD42021283922.
- Open Access
- 7 April 2022
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 148 (5) , 436-445
Association of Olfactory Impairment With All-Cause Mortality
Population-based studies of olfactory impairment (OI) indicate an overall prevalence ranging from 19% to 24%,1-3 with a prevalence exceeding 50% for individuals aged 65 to 80 years, and reaching 80% among those older than 80 years.4 Olfactory impairment is also associated with multiple comorbidities: neurogenerative,5-7 cardiovascular,8 nutritional,9 and immune disorders.10,11 Although OI is common, it frequently goes unnoticed compared with other senses, such as hearing or vision.3,12 Because olfaction is used for a variety of purposes and is a critical component of human physiology,13 its impairment may result in appetite suppression and malnutrition,9 decreased safety14 owing to increased risk of hazardous events (eg, cooking-related incidents, ingestion of spoiled food, and accidental gas poisoning), and overall lower quality of life.15
- 7 April 2022
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 148 (5) , 436-445
Open AccessAssociation of Olfactory Impairment With All-Cause Mortality
Population-based studies of olfactory impairment (OI) indicate an overall prevalence ranging from 19% to 24%,1-3 with a prevalence exceeding 50% for individuals aged 65 to 80 years, and reaching 80% among those older than 80 years.4 Olfactory impairment is also associated with multiple comorbidities: neurogenerative,5-7 cardiovascular,8 nutritional,9 and immune disorders.10,11 Although OI is common, it frequently goes unnoticed compared with other senses, such as hearing or vision.3,12 Because olfaction is used for a variety of purposes and is a critical component of human physiology,13 its impairment may result in appetite suppression and malnutrition,9 decreased safety14 owing to increased risk of hazardous events (eg, cooking-related incidents, ingestion of spoiled food, and accidental gas poisoning), and overall lower quality of life.15
- Open Access
- 22 March 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1260-1274
Neuroradiological Basis of COVID‐19 Olfactory Dysfunction: A Systematic Review and Meta‐Analysis
Objective: Olfactory dysfunction (OD) is a common presenting symptom of COVID‐19 infection. Radiological imaging of the olfactory structures in patients with COVID‐19 and OD can potentially shed light on its pathogenesis, and guide clinicians in prognostication and intervention.Methods: PubMed, Embase, Cochrane, SCOPUS were searched from inception to August 1, 2021. Three reviewers selected observational studies, case series, and case reports reporting radiological changes in the olfactory structures, detected on magnetic resonance imaging, computed tomography, or other imaging modalities, in patients aged ≥18 years with COVID‐19 infection and OD, following preferred reporting items for systematic reviews and meta‐analyses guidelines and a PROSPERO‐registered protocol (CRD42021275211). We described the proportion of radiological outcomes, and used random‐effects meta‐analyses to pool the prevalence of olfactory cleft opacification, olfactory bulb signal abnormalities, and olfactory mucosa abnormalities in patients with and without COVID‐19‐associated OD.Results: We included 7 case–control studies (N = 353), 11 case series (N = 154), and 12 case reports (N = 12). The pooled prevalence of olfactory cleft opacification in patients with COVID‐19 infection and OD (63%, 95% CI = 0.38–0.82) was significantly higher than that in controls (4%, 95% CI = 0.01–0.13). Conversely, similar proportions of cases and controls demonstrated olfactory bulb signal abnormalities (88% and 94%) and olfactory mucosa abnormalities (2% and 0%). Descriptive analysis found that 55.6% and 43.5% of patients with COVID‐19 infection and OD had morphological abnormalities of the olfactory bulb and olfactory nerve, respectively, while 60.0% had abnormal olfactory bulb volumes.Conclusion: Our findings implicate a conductive mechanism of OD, localized to the olfactory cleft, in approximately half of the affected COVID‐19 patients. Laryngoscope, 132:1260–1274, 2022
- 22 March 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1260-1274
Open AccessNeuroradiological Basis of COVID‐19 Olfactory Dysfunction: A Systematic Review and Meta‐Analysis
Objective: Olfactory dysfunction (OD) is a common presenting symptom of COVID‐19 infection. Radiological imaging of the olfactory structures in patients with COVID‐19 and OD can potentially shed light on its pathogenesis, and guide clinicians in prognostication and intervention.Methods: PubMed, Embase, Cochrane, SCOPUS were searched from inception to August 1, 2021. Three reviewers selected observational studies, case series, and case reports reporting radiological changes in the olfactory structures, detected on magnetic resonance imaging, computed tomography, or other imaging modalities, in patients aged ≥18 years with COVID‐19 infection and OD, following preferred reporting items for systematic reviews and meta‐analyses guidelines and a PROSPERO‐registered protocol (CRD42021275211). We described the proportion of radiological outcomes, and used random‐effects meta‐analyses to pool the prevalence of olfactory cleft opacification, olfactory bulb signal abnormalities, and olfactory mucosa abnormalities in patients with and without COVID‐19‐associated OD.Results: We included 7 case–control studies (N = 353), 11 case series (N = 154), and 12 case reports (N = 12). The pooled prevalence of olfactory cleft opacification in patients with COVID‐19 infection and OD (63%, 95% CI = 0.38–0.82) was significantly higher than that in controls (4%, 95% CI = 0.01–0.13). Conversely, similar proportions of cases and controls demonstrated olfactory bulb signal abnormalities (88% and 94%) and olfactory mucosa abnormalities (2% and 0%). Descriptive analysis found that 55.6% and 43.5% of patients with COVID‐19 infection and OD had morphological abnormalities of the olfactory bulb and olfactory nerve, respectively, while 60.0% had abnormal olfactory bulb volumes.Conclusion: Our findings implicate a conductive mechanism of OD, localized to the olfactory cleft, in approximately half of the affected COVID‐19 patients. Laryngoscope, 132:1260–1274, 2022
- Open Access
- 17 July 2018
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 9, 4-7
Developmental anomaly – A duplicate fronto-ethmoidal sinus complex
- 17 July 2018
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 9, 4-7
Open AccessDevelopmental anomaly – A duplicate fronto-ethmoidal sinus complex
- Open Access
- 19 March 2017
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 3 (1) , 24-31
Impact of endoscopic sinus surgery on otologic symptoms associated with chronic rhinosinusitis
Objective: To evaluate improvements in otologic symptoms after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS), and identify differences in symptoms, if any, between CRS patients with (CRSwNP) and without (CRSsNP) nasal polyposis. Material and methods This is a prospective multi-center observational cohort study. Adults with medically recalcitrant CRS who elected ESS were enrolled in a prospective, multi-center, observational cohort study between March, 2011 and October, 2014. Preoperative evaluation of subjects included assessment of clinical characteristics, measures of disease severity, and quality of life evaluation using the 22-item SinoNasal Outcome Test (SNOT-22). Postoperative improvement in otologic symptoms (ear fullness, dizziness, ear pain) scores were evaluated and compared between CRSwNP and CRSsNP subgroups. Results: Three hundred and ninety-five study patients completed both preoperative and postoperative evaluations, with an average follow-up of 13.9 months after ESS. The prevalence of patients reporting at least one otologic symptom preoperatively (87%) significantly decreased after ESS (63%, P < 0.001). Significant postoperative improvement across all otologic scores was also reported (P < 0.001). Relative mean improvement in otologic symptom severity was similar for both CRSwNP and CRSsNP, except patients with CRSwNP reported significantly greater postoperative improvement in ear fullness compared to CRSsNP (54% vs. 41%, P = 0.039). A total of 61%, 44%, and 43% of patients reported experiencing improvement in “ear fullness”, “dizziness” and “ear pain”, respectively. Conclusion: Sinus surgery significantly improves otologic symptoms associated with CRS. CRSwNP patients reported slightly greater relief of ear fullness than CRSsNP patients following ESS.
- 19 March 2017
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 3 (1) , 24-31
Open AccessImpact of endoscopic sinus surgery on otologic symptoms associated with chronic rhinosinusitis
Objective: To evaluate improvements in otologic symptoms after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS), and identify differences in symptoms, if any, between CRS patients with (CRSwNP) and without (CRSsNP) nasal polyposis. Material and methods This is a prospective multi-center observational cohort study. Adults with medically recalcitrant CRS who elected ESS were enrolled in a prospective, multi-center, observational cohort study between March, 2011 and October, 2014. Preoperative evaluation of subjects included assessment of clinical characteristics, measures of disease severity, and quality of life evaluation using the 22-item SinoNasal Outcome Test (SNOT-22). Postoperative improvement in otologic symptoms (ear fullness, dizziness, ear pain) scores were evaluated and compared between CRSwNP and CRSsNP subgroups. Results: Three hundred and ninety-five study patients completed both preoperative and postoperative evaluations, with an average follow-up of 13.9 months after ESS. The prevalence of patients reporting at least one otologic symptom preoperatively (87%) significantly decreased after ESS (63%, P < 0.001). Significant postoperative improvement across all otologic scores was also reported (P < 0.001). Relative mean improvement in otologic symptom severity was similar for both CRSwNP and CRSsNP, except patients with CRSwNP reported significantly greater postoperative improvement in ear fullness compared to CRSsNP (54% vs. 41%, P = 0.039). A total of 61%, 44%, and 43% of patients reported experiencing improvement in “ear fullness”, “dizziness” and “ear pain”, respectively. Conclusion: Sinus surgery significantly improves otologic symptoms associated with CRS. CRSwNP patients reported slightly greater relief of ear fullness than CRSsNP patients following ESS.